Glaukos/$GKOS
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Glaukos
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
- Ticker
- $GKOS
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 1,094
- Headquarters
- Aliso Viejo, United States
- Website
- www.glaukos.com
Glaukos Metrics
BasicAdvanced
$14B
-
-$2.91
0.69
-
Price and volume
Market cap
$14B
Beta
0.69
52-week high
$248.75
52-week low
$80.91
Average daily volume
1.2M
Financial strength
Current ratio
4.574
Quick ratio
3.841
Long term debt to equity
0.142
Total debt to equity
0.147
Interest coverage (TTM)
-12.83%
Profitability
EBITDA (TTM)
-20.012
Gross margin (TTM)
81.13%
Net profit margin (TTM)
-24.60%
Operating margin (TTM)
-8.95%
Effective tax rate (TTM)
2.70%
Revenue per employee (TTM)
$630,000
Management effectiveness
Return on assets (TTM)
-3.90%
Return on equity (TTM)
-22.84%
Valuation
Price to revenue (TTM)
20.089
Price to book
19.6
Price to tangible book (TTM)
26.56
Price to free cash flow (TTM)
385.002
Free cash flow yield (TTM)
0.26%
Free cash flow per share (TTM)
0.617
Growth
Revenue change (TTM)
46.94%
Earnings per share change (TTM)
87.93%
3-year revenue growth (CAGR)
31.50%
10-year revenue growth (CAGR)
21.13%
3-year earnings per share growth (CAGR)
2.70%
10-year earnings per share growth (CAGR)
48.08%
What the Analysts think about Glaukos
Analyst ratings (Buy, Hold, Sell) for Glaukos stock.
Analyst projections of the future price of Glaukos stock.
Bulls say / Bears say
Sales momentum is accelerating: third-quarter revenue rose 58% to $211 million, and Glaukos raised its 2026 sales outlook to $775–785 million while giving preliminary 2027 guidance of $1 billion. (Glaukos)
Epioxa is showing early commercial traction, with about $53 million in third-quarter sales as corneal-health revenue rose 154%; payer access pathways now cover around 90% of US commercial lives. (Glaukos)
Epioxa’s three-year follow-up showed sustained corneal improvement after one treatment, with no serious or treatment-related adverse events reported in the study. Durable results could support adoption of this less invasive keratoconus treatment. (Glaukos)
Medicare coverage remains a material uncertainty for iDose TR: five contractors proposed coverage criteria, and the company says the timing and impact of any final decisions are uncertain. (SEC)
The return to quarterly profit has not yet established sustained profitability: Glaukos still recorded a roughly $36 million operating loss over the first nine months of 2026, while third-quarter selling and research costs rose sharply. (Glaukos)
The established iStent franchise faces reimbursement and competitive pressure: Glaukos reported that lower physician fees and Medicare coverage decisions disrupted ordering and reduced US iStent sales volumes. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 29 Oct 2026.
Glaukos Financial Performance
Revenues and expenses
Glaukos Earnings Performance
Company profitability
Upcoming events
No upcoming events
Glaukos News
AllArticlesVideos
Funds containing Glaukos
AllUSDEURGBP
Fund name | Fund size | $GKOS weighting |
|---|---|---|
iShares Ageing Population$AGED | $953M | 0.92% |
iShares Ageing Population€AGED | $903M | 0.92% |
iShares Ageing Population£AGES | $953M | 0.92% |
iShares S&P SmallCap 600$IDP6 | $3.2B | 0.81% |
iShares S&P Small Cap 600£ISP6 | $3.2B | 0.81% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.